Mitral Valve Prolapse (MVP) is a common heart valve condition characterized by the improper closing of the valve between the heart's upper and lower left chambers, the atrium and ventricle. In individuals with MVP, the valve's flaps, known as leaflets, bulge or collapse backward into the atrium, causing a regurgitation of blood. While many people with MVP may not experience symptoms, others may encounter chest pain, palpitations, or fatigue. The exact cause of MVP is often unknown, but it can be associated with connective tissue disorders. Diagnosis typically involves echocardiography, which allows visualization of the valve's structure and function. Treatment is often unnecessary for those without symptoms, but in severe cases, medications or, in rare instances, surgery may be recommended to repair or replace the valve. Regular monitoring and consultation with healthcare professionals are essential for managing Mitral Valve Prolapse effectively.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation